Authors
Latest:
Steroid Therapy for cGVHDPanelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.
Latest:
New Method Unlocks Treatment for Melanoma's Brain InvasionVincent Law, research associate at Moffitt Cancer Center, discusses the key takeaways and implications of this research.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Choosing Second-Line Therapy for HCC After Atezolizumab/BevacizumabDaneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.
Latest:
PARP Inhibitor-Resistant Ovarian Cancer Responds to PARP Plus ATR InhibitorsStephanie L. Wethington, MD, MSc, discusses results of a study of olaparib plus ceralasertib for overcoming resistance to PARP inhibition.
Latest:
Case-Based Discussion: Management Strategies for Hydroxyurea-Resistant Polycythemia VeraPanelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ongoing symptoms), with experts advocating for either second-line ruxolitinib for rapid symptom and hematologic control or interferons (particularly in younger patients), while emphasizing the importance of addressing modifiable cardiovascular risk factors like smoking cessation.
Latest:
Managing Toxicity Seen With Linvoseltamab in R/R Multiple MyelomaHans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.
Latest:
Unmet Needs for Managing CRS and ICANS Due to CAR T-Cell TherapyNicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.
Latest:
Mehta on the Phase 3 METIS Trial of TTFields for Brain Metastases in NSCLCMinesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.
Latest:
Talquetamab/Daratumumab Demonstrates Promising Efficacy in Relapsed/Refractory Multiple MyelomaIn TRIMM-2, an overall response rate of 82% was seen amon patients given talquetamab plus daratumumab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Latest:
Future Perspectives on the Treatment of R/R Multiple MyelomaCaitlin Costello, MD, looks to the future of treating patients with relapsed/refractory multiple myeloma, highlighting potential opportunities and challenges in the therapeutic landscape.
Latest:
Community Oncologist Perspective: Future of Bispecific Therapies for NHLDr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Latest:
Future Outlooks for CAR T in Early R/R Multiple MyelomaPanelists discuss how chimeric antigen receptor (CAR) T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before patients develop treatment resistance.
Latest:
Schroeder on the Evolving Ovarian Cancer Treatment LandscapeEric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.
Latest:
Insights on Tucatinib Regimens in HER2+ Breast Cancer TreatmentSarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer treatment
Latest:
Treating Asymptomatic Patients With Polycythemia VeraJerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.
Latest:
Discussing Modakafusp Alfa as a Potential Treatment in RRMMDan T. Vogl, MD, MSCE, discusses the mechanism of action of modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.
Latest:
5-Year Data Supports Nadofaragene Firadenovec in BCG-Unresponsive NMIBCVikram Narayan, MD, discusses the significance of the 5-year overall survival and cystectomy-free survival rates of nadofaragene firadenovec-vncg in treating patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Latest:
MRD in Ph+ ALL: How Do You Measure It and What Does It Mean?Although it is well-established that MRD negativity plays an important prognostic role in Ph-positive ALL, the optimal method to assess MRD in this disease and how to use this information therapeutically are still being established.
Latest:
Unmet Needs and Future Directions for Ovarian CancerThomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.
Latest:
Expanding 177Lutetium-PSMA-617 Use in the CommunityTraining at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Latest:
Novel Treatment Approaches in Relapsed/Refractory Mantle Cell LymphomaManagement of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.
Latest:
Metastatic Breast Cancer Awareness Day: Assessing the Role of ADCsMuhammad Imam, MD, reviews the use of newer antibody-drug conjugates for patients with metastatic breast cancer across subtypes.
Latest:
Roundtable Discussion: Participants Explore Molecular Testing in the Lung Cancer SettingA 59-year-old man presented with dyspnea on exertion, fatigue, anorexia, and a 5-lb weight loss. He received the diagnosis of stage IVA adenocarcinoma and had an ECOG performance status of 1.
Latest:
Safety of TKIs in Treatment of Differentiated Thyroid CancerWarren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.
Latest:
Ring Sideroblasts Status Affects Treatment Decisions for Frontline MDSAmer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes.
Latest:
Patient Case: 67-Year Old Female With Advanced SCLCFederico Albrecht, MD, discusses the challenging case of a 67-year-old heavy smoker who presented with small cell lung cancer.
Latest:
Next Steps in Anal Carcinoma ResearchCharles J. Schneider, MD, FACP, discusses some of the ongoing research examining patients with anal cell carcinoma.
Latest:
Previous Liver Infection Requires a Rapid and Flexible Treatment Response in NSCLCJorge A. Rios, MD, a medical oncologist at Zangmeister Cancer Center in Columbus, Ohio, part of the American Oncology Network, shared the case of a woman who developed multiple severe adverse events attributable to durvalumab.
Latest:
World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and TreatmentLynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.
